Eisai Co., Ltd. and Biogen, Inc. have accomplished something that no other pharmaceutical company has done before – they demonstrated that an anti-amyloid antibody can improve cognition and function in Alzheimer's patients in a Phase III trial.
News that treatment with the anti-amyloid beta protofibril antibody lecanemab slowed the clinical decline of patients with early Alzheimer's disease...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)